51. Poorly Differentiated Neuroendocrine Larynx Carcinoma: Clinical Features and miRNAs Signature—A New Goal for Early Diagnosis and Therapy?
- Author
-
Ferdinando Riccardi, Brigida Iorio, Giuseppe Longo, Gabriella Misso, Giuseppe Lo Russo, Raffaele Addeo, Anna Maria Grimaldi, Marianna Scrima, Marianna Abate, Filippo Ricciardiello, Alessandro Ottaiano, Michela Falco, Alessia Maria Cossu, Raul Pellini, Marco Bocchetti, Alfonso Scarpa, Takashi Takeuchi, Giovanni Motta, Giuseppe Tortoriello, Michele Caraglia, Ciro Coppola, Amedeo Boscaino, Ricciardiello, F., Falco, M., Tortoriello, G., Riccardi, F., Pellini, R., Iorio, B., Russo, G., Longo, G., Coppola, C., Takeuchi, T., Grimaldi, A., Abate, M., Scrima, M., Cossu, A. M., Addeo, R., Ottaiano, A., Scarpa, A., Boscaino, A., Motta, G., Caraglia, M., Bocchetti, M., and Misso, G.
- Subjects
Oncology ,Larynx ,medicine.medical_specialty ,poorly differentiated ,carcinoma ,Article ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,microRNA ,Carcinoma ,medicine ,neuroendocrine ,squamous ,Pathological ,miRNA ,030304 developmental biology ,larynx ,0303 health sciences ,business.industry ,Poorly differentiated ,General Medicine ,medicine.disease ,Larynx carcinoma ,medicine.anatomical_structure ,Therapy response ,030220 oncology & carcinogenesis ,Medicine ,Who classification ,business - Abstract
Laryngeal neuroendocrine carcinomas (LNECs) are rare and highly heterogeneous malignancies presenting a wide range of pathological and clinical manifestations. Herein, we retrospectively characterize ten patients diagnosticated with LNEC, five of which were defined as well-moderately differentiated neuroendocrine carcinomas, and five that were defined as poorly differentiated neuroendocrine carcinomas, according to the latest WHO classification. Clinical features were analyzed and compared between the two subgroups together with a microRNA study which evidenced a peculiar signature likely related to poorly differentiated larynx neuroendocrine carcinomas. These findings may offer new useful insights for clinicians to improve diagnosis efficiency, therapy response, and patients’ outcome for this aggressive neoplasm.
- Published
- 2021